-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
Analysis of the technical features of the iHuPBMC-B platform of InnoModels Biotechnology
Author:
InnoModels
Release time:
2024-08-23
At the forefront of biomedical research, especially in the fields of tumor immunity, autoimmune diseases, and vaccine development, an efficient and accurate animal model system is crucial for promoting scientific research and technological innovation. With its self-developed iHuPBMC-B platform, InnoModels Biotechnology provides a revolutionary solution for researchers in these fields. This article will introduce the core technical features of iHuPBMC-B platform in detail.
1. Innovative Humanized B Cell Reconstruction Technology
The core advantage of iHuPBMC-B platform lies in its innovative humanized B cell reconstruction technology. This technology has successfully introduced B cells from human peripheral blood mononuclear cells (PBMC) into immunodeficient mice, realizing efficient reconstruction and stable expression of B cells. This breakthrough not only retains the advantages of easy operation and lower cost of the PBMC model, but also overcomes the limitation of the lack of function of human B cells in the traditional model, providing a more realistic and complete simulation environment for the study of human immune response.
2、Simulate the real humoral immune process
The iHuPBMC-B platform is capable of simulating the complete humoral immune process from antigen recognition, B cell activation, antibody generation to effector play. This high level of simulation capability enables researchers to observe human-like immune responses in the laboratory, thus more accurately assessing the efficacy, mechanism and safety of immunotherapy. In addition, the platform has the ability to parse complex immune networks, helping to reveal key molecules and signaling pathways in immune responses.
3. High reconstruction efficiency and stability
Compared with traditional humanized animal models, the iHuPBMC-B platform excels in reconstruction efficiency and stability. The platform adopts advanced cell culture technology and optimized mouse strains, which significantly improves the reconstruction success rate of B cells and ensures the stability of the model in a long period of time. This high efficiency and stability makes the iHuPBMC-B platform an indispensable tool in biomedical research.

4. Wide application potential
The iHuPBMC-B platform has a wide range of application potentials, covering tumor immunity, autoimmune diseases, infectious diseases and vaccine development. In tumor immunity research, the platform can be used to assess the immunogenicity of tumor vaccines, the efficacy of immunotherapy, and the immunoregulatory mechanism of the tumor microenvironment; in autoimmune disease research, it can be used to explore the immunopathological mechanism of disease development and the development of new therapeutic methods; in infectious disease research, it can be used to study the interaction between pathogens and the host immune system as well as the protective effect of vaccines. V. Provide customized services
5、Provide customized services
InnoModels Biotechnology understands the uniqueness and individual needs of each research project. Therefore, iHuPBMC-B platform not only provides standardized technical solutions, but also customized services for customers. From experimental design, model building to data analysis, the expert team of InnoModels Biotechnology will be involved in the whole process to ensure that the customer's research project can be carried out smoothly and achieve the expected results.
6、Promote the development of biomedical research
The emergence of iHuPBMC-B platform has undoubtedly injected new vitality into biomedical research. With its unique technical features and wide application potential, it provides researchers with a powerful tool to promote the rapid development of tumor immunity, autoimmune diseases, and vaccine research and development. In the future, with the continuous progress and improvement of the technology, the iHuPBMC-B platform is expected to play an important role in more fields and make greater contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd